Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.

ABSTRACT:

Background & aims

Detailed hepatitis C virus (HCV) kinetics modelling is scarce in patients with advanced liver disease receiving direct-acting antivirals (DAAs). Due to budget restrictions, patients and health systems would benefit from the shortest possible treatment course. We investigated whether modelling very early HCV kinetics in cirrhotic patients under DAAs therapy could be used to individualize care and reduce treatment duration to achieve cure.

Methods

We included 74 patients with HCV-related cirrhosis who received interferon-free treatments for 12-24 weeks. HCV genotype, liver disease stage and treatment regimen were recorded. Viral load was determined prospectively at very frequent intervals until target not detected (TND, <15 IU/mL). A viral kinetic model was u

SUBMITTER: Gambato M 

PROVIDER: S-EPMC6483833 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature